Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced the creation of a new cardiovascular development partnership.

Cardurion, a recently launched Boston-area based biotechnology company, is focused on the development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases.

Cardurion is led by two physician scientists with extensive experience in cardiovascular science, medicine and drug development- Daniel Bloomfield, M.D., chief executive officer, and Michael Mendelsohn, M.D., founder and executive chairman.

Takeda will jumpstart the new company’s discovery efforts by providing a 12-person cardiovascular research team from its Shonan, Japan site, including fully equipped laboratory space, development resources and licenses to a portfolio of preclinical-stage cardiovascular drug programmes.

The newly formed Cardurion is headquartered in Cambridge, Massachusetts and has research facilities in Shonan, Japan with both locations surrounded by leading academic research ecosystems that support biotechnology and pharmaceutical companies.